A pilot single-centre randomised controlled trial of recombinant human erythropoietin versus placebo in primary progressive multiple sclerosis.
- Registry ID
- EUCTR2008-005125-11
- Source registry
- EUCTR
- Status
- Prematurely Ended
- Phase
- PHASE2
- Sponsor
- Walton Centre for Neurology and Neurosurgery
- Start date
- 2008-12-04
- Completion date
- 2009-10-01
- Last update
- 2026-08-16
Conditions
- Primary progressive multiple sclerosis
Summary
To assess the size of the effect, if any, of recombinant human erythropoietin (rhEPO) in improving symptoms of primary progressive multiple sclerosis (PPMS), as measured by Maximum Walking Distance, Multiple Sclerosis Functional Composite (MSFC), Expanded Disability Status Scale (EDSS), Multiple Sclerosis Impact Scale 29 (MSIS), and Neurological Fatigue Index (NFI).
Locations
View on source registry